Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.50 USD
Change Today +0.05 / 1.45%
Volume 552.8K
ACRX On Other Exchanges
As of 5:20 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

acelrx pharmaceuticals inc (ACRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/7/14 - $11.65
52 Week Low
05/5/15 - $2.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acelrx pharmaceuticals inc (ACRX) Related Bloomberg News

View More Bloomberg News

acelrx pharmaceuticals inc (ACRX) Related Businessweek News

No Related Businessweek News Found

acelrx pharmaceuticals inc (ACRX) Details

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company’s lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting. The company is also developing ARX-04, a sufentanil single-dose tablet, which has been planned to initiate Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as in the emergency room, hospital floor, ambulatory care facilities, or on the battlefield. In addition, its product candidate pipeline consists of ARX-02, a pain management system that has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a single, fixed-dose, and combination drug product, which has been completed Phase II clinical trial designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

36 Employees
Last Reported Date: 05/5/15
Founded in 2005

acelrx pharmaceuticals inc (ACRX) Top Compensated Officers

Co-Founder, Chief Medical Officer and Directo...
Total Annual Compensation: $421.0K
Chief Financial Officer and Head of Business ...
Total Annual Compensation: $288.4K
Chief Development Officer
Total Annual Compensation: $310.3K
Chief Engineering Officer
Total Annual Compensation: $310.3K
Compensation as of Fiscal Year 2014.

acelrx pharmaceuticals inc (ACRX) Key Developments

AcelRx Pharmaceuticals Wins $17 Million Contract from Department of Defense to Advance Pain Drug

AcelRx Pharmaceuticals won contract worth up to $17 million from the United States Army Medical Research and Materiel Command to advance the development of its ARX-04 treatment of moderate-to-severe acute pain in a medically supervised setting. The drug is ARX-04 is in development as a non-invasive, single-use 30 mcg sufentanil sublingual tablet in a disposable, pre-filled, single-dose applicator. Under the terms of the contract, the Department of Defense will reimburse AcelRx for costs incurred for development, manufacturing and clinical costs outlined in the contract, including reimbursement for certain personnel and overhead expenses. These development activities are intended to include completion of the Phase 3 clinical program and manufacturing development activities over the next 18-months.

AcelRx Pharmaceuticals Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

AcelRx Pharmaceuticals reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss of $10.0 million or $0.27 diluted net loss per share compared to a net loss of $9.6 million or $0.22 basic and diluted net loss per share for the first quarter of 2014. The increase in the net loss and net loss per share was due primarily to higher headcount related expenses in the first quarter of 2015 as compared to the first quarter of 2014. Collaboration agreement revenue was $181,000 against $95,000 a year ago. Loss from operations was $11,400,000 against $8,541,000 a year ago. The increase in net loss and net loss per share was due primarily to higher headcount related expenses in the first quarter of 2015 as compared to the first quarter of 2014.

AcelRx Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 04, 2015

AcelRx Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 04, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACRX:US $3.50 USD +0.05

ACRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.5x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACELRX PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at